* Eloxx Pharmaceuticals Inc ELOX.OQ ELOX.O is expected
to show
a rise in quarterly revenue when it reports results on August
15 (estimated).
* The Watertown Massachusetts-based company is expected to
report
revenue of $2.333 million, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Eloxx
Pharmaceuticals Inc
is for a loss of 10 cents per share. For the same quarter last
year, the company reported a loss of 20 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Eloxx
Pharmaceuticals Inc is $1.5, above its last closing price
of $0.27.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.10 -0.09 -0.13 Missed -40.5
Dec. 31 2022 -0.12 -0.12 -0.14 Missed -16.7
Sep. 30 2021 -0.13 -0.13 -0.11 Beat 18.5
Jun. 30 2021 -0.13 -0.14 -0.20 Missed -45.5
Mar. -0.16 -0.16 -0.22 Missed -37.5
31 2021
Dec. 31 2020 -0.21 -0.15 Beat 30.2
Sep. 30 2020 -0.20 -0.19 -0.16 Beat 17.8
Jun. 30 2020 -0.21 -0.21 -0.20 Beat 5.5
This summary was machine generated August 12 at 11:15 GMT. All
figures in US dollars unless otherwise stated